Comparison of Chronocort Versus Standard Hydrocortisone Replacement Therapy in Participants Aged 16 Years and Over With Congenital Adrenal Hyperplasia (CONnECT)

A Randomized, Double-Blind, Active-Controlled, Phase 3 Study of Chronocort Compared With Immediate-Release Hydrocortisone Replacement Therapy in Participants Aged 16 Years and Over With Congenital Adrenal Hyperplasia

This study is a randomized, double-blind, active-controlled, phase III study of Chronocort® compared with immediate-release hydrocortisone replacement therapy in participants aged 16 years and over with Congenital Adrenal Hyperplasia.

Study Overview

• Status: Completed
• Conditions: Congenital Adrenal Hyperplasia
• Intervention / Treatment: Other: Placebo; Drug: Chronocort; Drug: Cortef

Detailed Description

The study will compare the efficacy, safety and tolerability of twice daily Chronocort with twice daily immediate release hydrocortisone replacement therapy (IRHC) (Cortef®) in participants aged 16 years and over with known classic Congenital Adrenal Hyperplasia (CAH) due to 21 hydroxylase deficiency.

• Study Type: Interventional
• Enrollment (Actual): 55
• Phase: Phase 3

Contacts and Locations

Study Locations

• France
  • Bordeaux, France, 33604
    • Diurnal Investigational Site in Pessac
  • Lyon, France, 69677
    • Diurnal Investigational Site in Bron
  • Paris, France, 75651
    • Diurnal Investigational Site in Paris
  • Toulouse, France, 31059
    • Diurnal Investigational Site in Toulouse (Children's Hospital)
  • Toulouse, France, 31059
    • Diurnal Investigational Site in Toulouse
  • Normandy
    • Caen, Normandy, France, 14033
      • Diurnal Investigational Site in Caen
• Japan
  • Kanagawa
    • Yokohama-shi, Kanagawa, Japan, 241-0811
      • Diurnal Investigational Site in Asahi-ku
  • Tokyo
    • Bunkyō-Ku, Tokyo, Japan, 113-8519
      • Diurnal Investigational Site in Yushima
    • Setagaya-Ku, Tokyo, Japan, 157-8535
      • Diurnal Investigational Site in Okura
    • Shinjuku-Ku, Tokyo, Japan, 162-8655
      • Diurnal Investigational Site in Toyama
• United States
  • California
    • Los Angeles, California, United States, 90027
      • Diurnal Investigational Site in Los Angeles
    • Orange, California, United States, 92868
      • Diurnal Investigational Site in Orange
  • Florida
    • Jacksonville, Florida, United States, 32207
      • Diurnal Investigational Site in Jacksonville
  • Iowa
    • Iowa City, Iowa, United States, 52224
      • Diurnal Investigational Site in Iowa
  • Maryland
    • Bethesda, Maryland, United States, 20892-1932
      • Diurnal Investigational Site in Maryland
  • Michigan
    • Ann Arbor, Michigan, United States, 48109
      • Diurnal Investigational Site in Michigan
  • Minnesota
    • Rochester, Minnesota, United States, 55901
      • Diurnal Investigational Site in Rochester
  • Nevada
    • Las Vegas, Nevada, United States, 89148
      • Diurnal Investigational Site in Nevada
  • Texas
    • Dallas, Texas, United States, 75235
      • Diurnal Investigational Site in Dallas
  • Washington
    • Seattle, Washington, United States, 98105
      • Diurnal Investigational Site in Seattle
  • Wisconsin
    • Milwaukee, Wisconsin, United States, 53226
      • Diurnal Investigational Site in Milwaukee

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years and older (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Male or female participants must be aged 16 years or older at the time of signing the informed consent/assent.
• In participants aged <18 years, height velocity must be less than 2 cm/year in the last year and puberty must be completed (Tanner stage V).
• Participants with known classic CAH due to 21 hydroxylase deficiency diagnosed in childhood with documented (at any time) elevated 17-OHP and with or without elevated A4 and currently treated with hydrocortisone, prednisone, prednisolone or dexamethasone (or a combination of the aforementioned glucocorticoids) and on stable glucocorticoid therapy for a minimum of 3 months.
• Participants who are receiving fludrocortisone must be on a documented stable dose for a minimum of 3 months prior to enrollment and must have stable renin levels at screening.
• Female participants of childbearing potential and all male participants must agree to the use of an accepted method of contraception during the study.
• A female participant is eligible to participate if she is not pregnant, not breastfeeding, and she is either not a woman of childbearing potential (WOCBP) or has a negative pregnancy test at entry into the study. Note: females presenting with oligomenorrhea or amenorrhea who are aged ≤55 years should be considered potentially fertile and therefore should undergo pregnancy testing like all other female participants.
• Capable of giving signed informed consent/assent which includes compliance with requirements and restrictions listed in the informed consent form (ICF) and in this protocol.

Exclusion Criteria:

• Clinical or biochemical evidence of hepatic or renal disease e.g. creatinine >2 times the upper limit of normal (ULN) or elevated liver function tests (alanine aminotransferase [ALT] or aspartate aminotransferase [AST] >2 times the ULN).
• History of bilateral adrenalectomy.
• History of malignancy (other than basal cell carcinoma successfully treated >26 weeks prior to entry into the study).
• Participants who have type 1 diabetes or receive regular insulin, have uncontrolled diabetes, or have a screening HbA1c greater than 8%.
• Persistent signs of adrenal insufficiency or the participant does not tolerate treatment at the end of the 4-week run-in period.
• Participants with any other significant medical or psychiatric conditions that in the opinion of the Investigator would preclude participation in the study.
• Participants on regular daily inhaled, topical, nasal or oral steroids for any indication other than CAH.
• Co-morbid condition requiring daily administration of a medication or consumption of any material that interferes with the metabolism of glucocorticoids.
• Participants who are receiving <10 mg hydrocortisone dose at screening or the hydrocortisone dose equivalent.
• Participants anticipating regular prophylactic use of additional steroids e.g. for strenuous exercise.
• Participation in another clinical study of an investigational or licensed drug or device within the 12 weeks prior to screening.
• Inclusion in any natural history or translational research study that would require evaluation of androgen levels during the study period outside of this protocol's assessments.
• Participants who have previously been exposed to Chronocort in any Diurnal study.
• Participants who routinely work night shifts and so do not sleep during the usual night-time hours.
• Participants, who in the opinion of the Investigator, will be unable to comply with the requirements of the protocol.
• Participants with a known hypersensitivity to any of the components of the Chronocort capsules, the Cortef tablets, or the placebo capsules.
• Participants with congenital galactosemia, malabsorption of glucose and galactose, or who are lactase deficient.
• Participants with a body weight of 45 kg or less.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Chronocort; Participants received Chronocort at a starting dose of 30 milligrams (mg), with dose adjustments down to 25, 20, or 15 mg based on adrenal insufficiency symptoms and androgen levels. Placebo was used for dose adjustment to maintain blinding.	Other: Placebo; Matching placebo; Drug: Chronocort; Over-encapsulated hydrocortisone modified-release capsule for oral administration.; Other Names: Hydrocortisone modified-release
Active Comparator: Cortef; Participants received Cortef at a starting dose of 30 mg, with dose adjustments down to 25, 20, or 15 mg based on adrenal insufficiency symptoms and androgen levels. Placebo was used for dose adjustment to maintain blinding.	Other: Placebo; Matching placebo; Drug: Cortef; Over-encapsulated hydrocortisone immediate-release tablet for oral administration.; Other Names: Immediate-release hydrocortisone; IRHC

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Participants Who Were Biochemical Responders at Week 28	Biochemical response was defined as a participant who a) was in biochemical control at the 08:00 assessment and b) was receiving a total daily dose of hydrocortisone of not more than 25 mg if the participant was in biochemical control at baseline or not more than 30 mg if the participant was not in biochemical control at baseline. Biochemical control was defined as both a 17-OHP concentration equal to or below the upper limit for optimal control (1200 ng/dL [36.4 nmol/L]) and an A4 concentration equal to or below the upper limit of the reference range (150 ng/dL [5.2 nmol/L] for men and 200 ng/dL [7.0 nmol/L] for women). Assessment of efficacy at Week 28 was a composite of each participant's on-treatment visit closest in time to 28 weeks post randomization.	Week 28

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Participants Who Were Dose Responders at Week 28	Dose response was defined as a participant who a) was receiving a total daily dose of hydrocortisone of not more than 25 mg and b) was in biochemical control at the 08:00 assessment. Assessment of efficacy at Week 28 was a composite of each participant's on-treatment visit closest in time to 28 weeks post randomization.	Week 28
Total Daily Dose of Hydrocortisone at Week 28	Least squares (LS) mean was assessed using mixed model repeated measures (MMRM). Assessment of efficacy at Week 28 was a composite of each participant's on-treatment visit closest in time to 28 weeks post randomization.	Week 28
Number of Participants in Biochemical Control	Biochemical control was defined as both a 17-OHP concentration (assessed at 08:00) equal to or below the upper limit for optimal control (1200 ng/dL [36.4 nmol/L]) and an A4 concentration equal to or below the upper limit of the reference range (150 ng/dL [5.2 nmol/L] for men and 200 ng/dL [7.0 nmol/L] for women). Assessment of efficacy at Week 28 was a composite of each participant's on-treatment visit closest in time to 28 weeks post randomization.	Baseline and Week 28
Change From Baseline in Mean of 08:00 and 13:00 17-OHP Levels at Week 28	LS mean was assessed using analysis of covariance (ANCOVA). Assessment of efficacy at Week 28 was a composite of each participant's on-treatment visit closest in time to 28 weeks post randomization.	Baseline, Week 28
Change From Baseline in Mean of 08:00 and 13:00 A4 Levels at Week 28	LS mean was assessed using ANCOVA. Assessment of efficacy at Week 28 was a composite of each participant's on-treatment visit closest in time to 28 weeks post randomization.	Baseline, Week 28
Number of Participants With Menstrual Regularity (Females of Childbearing Potential Only) at Week 28	Data are presented for the number of participants with more than monthly menstrual cycles, monthly menstrual cycles, and number of participants with oligomenorrhoea and amenorrhoea. Oligomenorrhoea was defined as fewer than 9 menstrual cycles per year or cycle length >35 days and amenorrhoea as absent menses for ≥ 3 months. Assessment of efficacy at Week 28 was a composite of each participant's on-treatment visit closest in time to 28 weeks post randomization.	Week 28
Change From Baseline in Luteinizing Hormone Levels (Males Only) at Week 28	LS mean was assessed using ANCOVA. Assessment of efficacy at Week 28 was a composite of each participant's on-treatment visit closest in time to 28 weeks post randomization.	Baseline, Week 28
Percent Change From Baseline in Size of Testicular Adrenal Rest Tumors at Week 28 (Males Only)	Assessment of efficacy at Week 28 was a composite of each participant's on-treatment visit closest in time to 28 weeks post randomization.	Week 28
Change From Baseline in Hirsutism at Week 28 Using the Ferriman-Gallwey Score (Females Only) at Week 28	Ferriman-Gallwey score is a method used to assess and quantify hirsutism in women. A total score < 8 is considered normal whereas a score of 8 to 15 indicates mild hirsutism. A score >15 indicates moderate or severe hirsutism. The Ferriman-Gallwey score ranged from 0 to 36. Higher score indicated more hirsutism. Change from baseline is reported (negative change from baseline indicated improvement). LS mean was assessed using ANCOVA. Assessment of efficacy at Week 28 was a composite of each participant's on-treatment visit closest in time to 28 weeks post randomization.	Baseline, Week 28
Change From Baseline in Acne Using the Global Evaluation Acne (GEA) Scale (Females Only) at Week 28	Acne severity was assessed according to GEA scale, which ranged from 0 (Clear. No lesions) to 5 (Very severe). Higher score indicated higher severity of acne. Change from baseline is reported (negative change from baseline indicated improvement). LS mean was assessed using ANCOVA. Assessment of efficacy at Week 28 was a composite of each participant's on-treatment visit closest in time to 28 weeks post randomization.	Baseline, Week 28
Change From Baseline in Glycated Hemoglobin (HbA1c) Percent Levels at Week 28	LS mean was assessed by ANCOVA. Assessment of efficacy at Week 28 was a composite of each participant's on-treatment visit closest in time to 28 weeks post randomization.	Baseline, Week 28
Change From Baseline in Waist Circumference at Week 28	LS mean was assessed using ANCOVA. Assessment of efficacy at Week 28 was a composite of each participant's on-treatment visit closest in time to 28 weeks post randomization.	Baseline, Week 28
Change From Baseline in Body Weight at Week 28	LS mean was assessed by ANCOVA. Assessment of efficacy at Week 28 was a composite of each participant's on-treatment visit closest in time to 28 weeks post randomization.	Baseline, Week 28
Change From Baseline Quality of Life Using the Self-completed Medical Outcome Study 36-Item Short Form Health Survey (SF-36) Total Score for the Physical and Mental Components and the Sub-domain of Vitality at Week 28	SF-36 evaluates aspects of functional health and well-being. The physical component has 4 sub-scales: physical function, role limitations due to physical problems, pain, and general health perception; and the mental component has 4 sub-scales: vitality, social function, role limitations due to emotional problems, and mental health. Total scores for the physical and mental component are presented as well as the sub-scale score for vitality. Scores were summarized and transformed into a range from 0 to 100; 0=worst, and 100=best outcome. Higher scores indicated better outcome. Change from baseline is reported (positive change from baseline indicated improvement). LS mean was assessed by ANCOVA. Assessment of efficacy at Week 28 was a composite of each participant's on-treatment visit closest in time to 28 weeks post randomization.	Baseline, Week 28

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
To compare Chronocort to IRHC in terms of net clinical benefit after 28 weeks of randomized treatment	This is one statistical measure of a combination of outcomes as listed below (menstrual regularity hirsutism, acne, TART, LH levels, sperm count, body weight, HbA1c, waist circumference, SF-36 and MAF). Outcomes for each measure are compared between individuals on a categorical basis - improved/not improved. Summary statistics of the outcomes show which arm has the most overall improvement in health status.	28 weeks
To compare Chronocort to IRHC in terms of net clinical benefit after 28 weeks of randomized treatment - Menstrual Regularity	The probability that a randomly chosen participant from the Chronocort arm shows more clinical benefit after 28 weeks of randomized treatment than a randomly chosen participant from the IRHC arm (the probability of net clinical benefit). The comparison between participants will be based on menstrual regularity, which is recorded using an electronic participant diary for all pre-menopausal women (only in pre menopausal women without hysterectomy and not using hormonal contraception)	28 weeks
To compare Chronocort to IRHC in terms of net clinical benefit after 28 weeks of randomized treatment - Hirsutism	The probability that a randomly chosen participant from the Chronocort arm shows more clinical benefit after 28 weeks of randomized treatment than a randomly chosen participant from the IRHC arm (the probability of net clinical benefit). The comparison between participants will be based on hirsutism (female only) using a Visual Analog Scale (VAS), which is a 10cm scale ranging from 'No Hair' to 'Most Hair Growth Ever Experienced' completed by participant and also objective hirsutism will be assessed by Investigator using the Ferriman-Gallway Score. A score of 1 to 4 is given for nine areas of the body. A total score less than 8 is considered normal, a score of 8 to 15 indicates mild hirsutism, and a score greater than 15 indicates moderate or severe hirsutism. A score of 0 indicates absence of terminal hair.	28 weeks
To compare Chronocort to IRHC in terms of net clinical benefit after 28 weeks of randomized treatment - Acne	The probability that a randomly chosen participant from the Chronocort arm shows more clinical benefit after 28 weeks of randomized treatment than a randomly chosen participant from the IRHC arm (the probability of net clinical benefit). The comparison between participants will be based on subjective acne (female only) using a Visual Analog Scale (VAS), which is a 10cm scale ranging from 'No Acne' to 'Worst Acne Ever' completed by the participant and also objective acne will be assessed using the Global Evaluation Acne (GEA) Scale, where a score of 1 to 5 is given by the Investigator, where 0 is 'Clear, no lesions', 1 is 'Almost clear. Almost no lesions', 2 is 'Mild', 3 is 'Moderate', 4 is 'Severe' and 5 is 'Very severe'.	28 weeks
To compare Chronocort to IRHC in terms of net clinical benefit after 28 weeks of randomized treatment - TART size	The probability that a randomly chosen participant from the Chronocort arm shows more clinical benefit after 28 weeks of randomized treatment than a randomly chosen participant from the IRHC arm (the probability of net clinical benefit). The comparison between participants will be based on TART size (men only) measured via ultrasound.	28 weeks
To compare Chronocort to IRHC in terms of net clinical benefit after 28 weeks of randomized treatment - LH Level	The probability that a randomly chosen participant from the Chronocort arm shows more clinical benefit after 28 weeks of randomized treatment than a randomly chosen participant from the IRHC arm (the probability of net clinical benefit). The comparison between participants will be based on LH levels (Men only).	28 weeks
To compare Chronocort to IRHC in terms of net clinical benefit after 28 weeks of randomized treatment - Sperm Count	The probability that a randomly chosen participant from the Chronocort arm shows more clinical benefit after 28 weeks of randomized treatment than a randomly chosen participant from the IRHC arm (the probability of net clinical benefit). The comparison between participants will be based on the sperm count (men only) measured by testing kit.	28 weeks
To compare Chronocort to IRHC in terms of net clinical benefit after 28 weeks of randomized treatment - Body weight	The probability that a randomly chosen participant from the Chronocort arm shows more clinical benefit after 28 weeks of randomized treatment than a randomly chosen participant from the IRHC arm (the probability of net clinical benefit). The comparison between participants will be based on body weight measured at every visit, with outer clothing and shoes removed.	28 weeks
To compare Chronocort to IRHC in terms of net clinical benefit after 28 weeks of randomized treatment - HbA1c	The probability that a randomly chosen participant from the Chronocort arm shows more clinical benefit after 28 weeks of randomized treatment than a randomly chosen participant from the IRHC arm (the probability of net clinical benefit). The comparison between participants will be based on HbA1c measured at each visit after visit 1.	28 weeks
To compare Chronocort to IRHC in terms of net clinical benefit after 28 weeks of randomized treatment - Waist Circumference	The probability that a randomly chosen participant from the Chronocort arm shows more clinical benefit after 28 weeks of randomized treatment than a randomly chosen participant from the IRHC arm (the probability of net clinical benefit). The comparison between participants will be based on waist circumference measured at every visit.	28 weeks
To compare Chronocort to IRHC in terms of net clinical benefit after 28 weeks of randomized treatment - SF-36®	The probability that a randomly chosen participant from the Chronocort arm shows more clinical benefit after 28 weeks of randomized treatment than a randomly chosen participant from the IRHC arm (the probability of net clinical benefit). The comparison between participants will be based on the self completed SF-36® total score. The SF-36 measures eight scales: physical functioning (PF), role physical (RP), bodily pain (BP), general health (GH), vitality (VT), social functioning (SF), role emotional (RE), and mental health (MH). All components contribute in different proportions to the overall measures. Where the minimum score is 0 and maximum score is 100 and a high score is a more favorable score.	28 weeks
To compare Chronocort to IRHC in terms of net clinical benefit after 28 weeks of randomized treatment - Multidimensional Assessment of Fatigue (MAF)	The probability that a randomly chosen participant from the Chronocort arm shows more clinical benefit after 28 weeks of randomized treatment than a randomly chosen participant from the IRHC arm (the probability of net clinical benefit). The comparison between participants will be based on the Multidimensional Assessment of Fatigue (MAF) score. The MAF is a 16 item scale that measures fatigue according to four dimensions: degree and severity, distress that it causes, timing of fatigue, and its impact on various activities of daily living, with a range of score from 1 - 10 per item to give a Global Fatigue Score of up to 50 with a high score indicating a worse outcome.	28 weeks
To investigate the correlation between biochemical control at 10, 16 and 28 weeks after randomization with the total daily dose at the corresponding timepoints.	At each of 10, 16 and 28 weeks after randomization, investigate the total daily dose of steroid in participants in biochemical control.	10, 16 and 28 weeks of randomized treatment
To compare Chronocort to IRHC in terms of the impact on QoL using the remaining self-completed SF-36® sub domains (excluding vitality).	The change from baseline to 4, 10, 16 and 28 weeks of randomized treatment in QoL using the remaining self-completed SF 36® sub-domains (excluding vitality) will be summarized and compared between treatment arms. The SF-36 measures eight scales: physical functioning (PF), role physical (RP), bodily pain (BP), general health (GH), vitality (VT), social functioning (SF), role emotional (RE), and mental health (MH). All components contribute in different proportions to the overall measures. Where the minimum score is 0 and maximum score is 100, a high score is a more favorable score.	Baseline to 4, 10, 16 and weeks of randomized treatment
To compare Chronocort to IRHC in terms of the impact on the bone marker of osteocalcin.	The change from baseline to 4, 10, 16 and 28 weeks of randomized treatment in osteocalcin levels will be summarized and compared between treatment arms.	Baseline to 4, 10, 16 and 28 weeks of randomized treatment
To compare Chronocort to IRHC in terms of the impact on alertness.	The change from baseline to 4, 10, 16 and 28 weeks of randomized treatment in alertness will be summarized and compared between treatment arms. Alertness will be assessed using a Visual Analog Scale (VAS), which is a 10cm scale ranging from 'Brain Fog: unable to perform normal daily tasks' to 'Fully Alert: able to perform normal daily tasks easily'. A higher score indicates a better outcome.	Baseline to 4, 10, 16 and 28 weeks of randomized treatment
To compare Chronocort to IRHC in terms of the impact on 11 ketotestosterone.	The change from baseline to the end of 28 weeks of randomized treatment in serum 11 ketotestosterone levels will be summarized and compared between treatment arms.	28 weeks
To compare Chronocort to IRHC in terms of the impact on dehydroepiandrosterone (DHEA)	The change from baseline to the end of 28 weeks of randomized treatment in serum DHEA levels will be summarized and compared between treatment arms.	28 weeks
To compare Chronocort to IRHC in terms of the impact on total testosterone	The change from baseline to the end of 28 weeks of randomized treatment in serum total testosterone will be summarized and compared between treatment arms by sex.	28 weeks
To compare Chronocort to IRHC in terms of the impact on follicle stimulating hormone (FSH) levels.	The change from baseline to 4, 10, 16 and 28 weeks of randomized treatment in FSH levels (women only) will be summarized and compared between treatment arms.	Baseline to 4, 10, 16 and 28 weeks of randomized treatment
To assess dose changes over the study period - Incidence	The incidence of dose changes at each visit up to the end of 28 weeks of randomized treatment and overall will be summarized by treatment arm.	28 weeks
To assess dose changes over the study period - Change in mg	The extent (in mg) of dose changes at each visit up to the end of 28 weeks of randomized treatment and overall will be summarized by treatment arm.	28 weeks
To assess preference for treatment.	Participant preference for assigned treatment after 28 weeks of randomized treatment compared with previous treatments will be summarized by treatment arm. Preference of treatment will be assessed using a Visual Analog Scale (VAS), which is a 10cm scale where 0 indicates 'Strongly agree' and 10 indicates 'Strongly disagree', when asked if the participant prefers the study medication over their usual Hydrocortisone medication.	28 weeks
To assess the safety and tolerability of Chronocort relative to IRHC.	The incidence, nature, severity, relatedness, duration, outcome, seriousness and expectedness of treatment emergent adverse events (TEAEs) will be tabulated by treatment arm. AEs of special interest will additionally be tabulated separately, with particular note of adrenal crises.	28 weeks
To assess the need for use of additional glucocorticoid doses by recording of use of stress dosing rules - Incidence of use	The use of medication from the stress dosing packs or use of any additional glucocorticoid treatment during the study will be tabulated by treatment arm and recorded as incidence of use.	28 weeks
To assess the need for use of additional glucocorticoid doses by recording of use of stress dosing rules - Duration of use	The use of medication from the stress dosing packs or use of any additional glucocorticoid treatment during the study will be tabulated by treatment arm and recorded as duration of use.	28 weeks
To assess the need for use of additional glucocorticoid doses by recording of use of stress dosing rules - Dose of steroid	The use of medication from the stress dosing packs or use of any additional glucocorticoid treatment during the study will be tabulated by treatment arm and recorded as dose of steroid (in mg).	28 weeks
To evaluate the safety of Chronocort compared to IRHC by assessment of safety laboratory assessments by number of participants with changes in safety laboratory assessments.	Safety laboratory assessments including hematology, clinical chemistry and urinalysis will be conducted at each visit after randomized treatment and their changes from baseline will be summarized by treatment arm and aggregated to number of participants with changes in safety laboratory assessments.	28 weeks (Assessed at baseline, 4, 10, 16 and 28 weeks)
To evaluate the safety of Chronocort compared to IRHC by assessment of physical examination by number of participants with changes in physical examination.	A full physical examination to assess the participant's general appearance and overall health will be carried out and aggregated to number of participants with changes in physical examination.	28 weeks (Assessed at baseline and 28 weeks)
To evaluate the safety of Chronocort compared to IRHC by assessment of vital signs by number of patients with changes in vital signs.	Vital signs will be measured at baseline, 4, 10, 16 and 28 weeks and their changes from baseline will be summarized by treatment arm and aggregated to number of participants with changes in vital signs.	28 weeks (Assessed at baseline, 4, 10, 16 and 28 weeks)
To evaluate the safety of Chronocort compared to IRHC by assessment of electrocardiogram (ECG) by number of patients with changes in ECG.	A single 12-lead ECG will be recorded at baseline and 28 weeks and their changes from baseline will be summarized by treatment arm and aggregated to number of participants with changes in ECG.	28 weeks (Assessed at baseline and 28 weeks)

Collaborators and Investigators

• Sponsor: Neurocrine UK Limited
• Investigators: Principal Investigator: Principal Investigator, Neurocrine UK Limited

Study record dates

Study Major Dates

• Study Start (Actual): May 24, 2022
• Primary Completion (Actual): February 2, 2024
• Study Completion (Actual): February 2, 2024

Study Registration Dates

• First Submitted: May 28, 2021
• First Submitted That Met QC Criteria: September 30, 2021
• First Posted (Actual): October 1, 2021

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: February 21, 2025
• Last Verified: February 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Urogenital Diseases; Endocrine System Diseases; Pathologic Processes; Male Urogenital Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Metabolism, Inborn Errors; Genetic Diseases, Inborn; Metabolic Diseases; Gonadal Disorders; Congenital Abnormalities; Adrenal Gland Diseases; Disorders of Sex Development; Urogenital Abnormalities; Steroid Metabolism, Inborn Errors; Hyperplasia; Adrenal Hyperplasia, Congenital; Adrenogenital Syndrome; Adrenocortical Hyperfunction; Anti-Inflammatory Agents; Hydrocortisone; Hydrocortisone 17-butyrate 21-propionate; Hydrocortisone acetate; Hydrocortisone hemisuccinate
• Other Study ID Numbers: DIUR-014

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No